AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed.
AZN Key Statistics
Stock Snapshot
With a market cap of 283.76B, AstraZeneca(AZN) trades at $91.37. The stock has a price-to-earnings ratio of 30.10 and currently yields dividends of 1.7%.
On 2025-12-22, AstraZeneca(AZN) stock moved within a range of $90.63 to $91.42. With shares now at $91.37, the stock is trading +0.8% above its intraday low and -0.1% below the session's peak.
Trading volume for AstraZeneca(AZN) stock has reached 403.21K, versus its average volume of 6.26M.
The stock's 52-week range extends from a low of $61.24 to a high of $94.02.
The stock's 52-week range extends from a low of $61.24 to a high of $94.02.
AZN News
The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ:AZN) to s...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
AstraZeneca’s (AZN) breast cancer drug Enhertu has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). The FDA gave th...
Analyst ratings
81%
of 32 ratingsMore AZN News
Enhertu has been granted breakthrough therapy designation in the U.S. for adult patients with HER2 positive early breast cancer with residual invasive disease i...
The first patient has been dosed in the DESTINY-Endometrial02 phase 3 trial evaluating Enhertu with or without radiotherapy compared to standard of care chemoth...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Niowave announced the expansion of its existing supply agreement with AstraZeneca (AZN) to a 10-year commitment to deliver Actinium-225 following AstraZeneca’s...
Daiichi Sankyo Company (DSKYF), AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence...
AstraZeneca (AZN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data an...